Here are the 424B prospectus supplements from GH Research PLC (GHRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GHRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GHRS filings page.
GH Research PLC intends to offer up to $200,000,000 of ordinary shares through an at‑the‑market sales agreement with Stifel, acting as agent. The prospectus supplement states sales may occur from time to time at prevailing market prices (the Agent may receive up to 3.0% commission).
The supplement shows an illustrative share count of up to 9,285,051 shares assuming sales at $21.54 (the last reported Nasdaq sale on May 12, 2026) and reports 62,052,506 shares outstanding as of March 31, 2026.
GH Research PLC is offering 6,527,779 ordinary shares. The prospectus supplement prices the shares at $18.00 per share for a total offering price of $117,500,022.00, with estimated net proceeds to the issuer of approximately $111.2 million.
The company says it will use proceeds to fund research, clinical and technical development, pre-commercial activities, working capital, capital expenditures and general corporate purposes. The prospectus supplement ties post-offering outstanding shares to a baseline of 68,557,174 ordinary shares and references 62,029,395 ordinary shares outstanding as of December 31, 2025.